Hyperperméabilité intestinale (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Hyperperméabilité intestinale" in French language version.

refsWebsite
Global rank French rank
2nd place
3rd place
4th place
12th place
57th place
4th place
222nd place
129th place
low place
low place
6,828th place
2,093rd place
low place
7,922nd place
1,226th place
347th place
low place
low place
low place
low place
1,989th place
4,421st place
low place
low place

aimspress.com

  • (en) Dario Siniscalco, Anna Lisa Brigida et Nicola Antonucci, « Autism and neuro-immune-gut link », Molecular 2018, Vol. 5, Pages 166-172,‎ (DOI 10.3934/molsci.2018.2.166, lire en ligne, consulté le )

bmj.com

gut.bmj.com

copmed.fr

doi.org

dx.doi.org

  • A. Goebel, S. Buhner, R. Schedel et H. Lochs, « Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome », Rheumatology, vol. 47, no 8,‎ , p. 1223–1227 (ISSN 1462-0324 et 1462-0332, DOI 10.1093/rheumatology/ken140, lire en ligne, consulté le )
  • (en) Laura de Magistris, Valeria Familiari, Antonio Pascotto et Anna Sapone, « Alterations of the Intestinal Barrier in Patients With Autism Spectrum Disorders and in Their First-degree Relatives », Journal of Pediatric Gastroenterology and Nutrition, vol. 51, no 4,‎ , p. 418–424 (ISSN 0277-2116, DOI 10.1097/MPG.0b013e3181dcc4a5, lire en ligne, consulté le )
  • Mariarosaria Di Pierro, Ruliang Lu, Sergio Uzzau et Wenle Wang, « Zonula Occludens Toxin Structure-Function Analysis », Journal of Biological Chemistry, vol. 276, no 22,‎ , p. 19160–19165 (ISSN 0021-9258 et 1083-351X, DOI 10.1074/jbc.m009674200, lire en ligne, consulté le )
  • Fasano A, « Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer », Physiol. Rev., vol. 91, no 1,‎ , p. 151–75 (PMID 21248165, DOI 10.1152/physrev.00003.2008)
  • (en) Mohan K. Raizada, Carl J. Pepine, Richard C. Holbert et Elaine M. Richards, « Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression », Gut, vol. 67, no 8,‎ , p. 1555–1557 (ISSN 0017-5749 et 1468-3288, PMID 28814485, PMCID PMC5851874, DOI 10.1136/gutjnl-2017-314759, lire en ligne, consulté le )
  • « Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine », Clinics (Sao Paulo), vol. 65, no 6,‎ , p. 635–43 (PMID 20613941, PMCID 2898551, DOI 10.1590/S1807-59322010000600012)
  • « Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis », Gut, vol. 61, no 9,‎ , p. 1355–64 (PMID 21890812, DOI 10.1136/gutjnl-2011-300327) :

    « Changes in intestinal paracellular and transcellular permeability appear secondary to the abnormal immune reaction induced by gluten. Gliadin was suggested to increase junction permeability to small molecules through the release of prehaptoglobin-2. Environmental triggers of CD other than gliadin may also promote changes in permeability. Intestinal infection and iron deficiency can stimulate the expression of the transferrin receptor (TfR) CD71 in enterocytes. ... Once established, the alterations in intestinal permeability, notably the retro-transport of IgA-gliadin peptides, might self-sustain the inflammatory immune responses and perpetuate a vicious circle. »

  • Khaleghi, Ju, Lamba et Murray, « The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate », Therapeutic Advances in Gastroenterology, vol. 9, no 1,‎ , p. 37–49 (ISSN 1756-283X, PMID 26770266, PMCID 4699279, DOI 10.1177/1756283X15616576)
  • Fasano A, « Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications », Clin Gastroenterol Hepatol, vol. 10, no 10,‎ , p. 1096–100 (PMID 22902773, PMCID 3458511, DOI 10.1016/j.cgh.2012.08.012)
  • Jose L Barboza, Michael S Okun et Baharak Moshiree, « The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease », Expert Opinion on Pharmacotherapy, vol. 16, no 16,‎ , p. 2449–2464 (ISSN 1465-6566 et 1744-7666, DOI 10.1517/14656566.2015.1086747, lire en ligne, consulté le )
  • Eveline Deloose et Jan Tack, « Redefining the functional roles of the gastrointestinal migrating motor complex and motilin in small bacterial overgrowth and hunger signaling », American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 310, no 4,‎ , G228–G233 (ISSN 0193-1857 et 1522-1547, DOI 10.1152/ajpgi.00212.2015, lire en ligne, consulté le )
  • (en) EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), « Scientific Opinion on the substantiation of health claims related to riboflavin (vitamin B2) and contribution to normal energy-yielding metabolism (ID 29, 35, 36, 42), contribution to normal metabolism of iron (ID 30, 37), maintenance of normal skin and m: Riboflavin related health claims », EFSA Journal, vol. 8, no 10,‎ , p. 1814 (DOI 10.2903/j.efsa.2010.1814, lire en ligne, consulté le )
  • (en) EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), « Scientific Opinion on the substantiation of health claims related to niacin and energy-yielding metabolism (ID 43, 49, 54), function of the nervous system (ID 44, 53), maintenance of the skin and mucous membranes (ID 45, 48, 50, 52), maintenance of normal: Niacin related health claims », EFSA Journal, vol. 7, no 10,‎ , p. 1224 (DOI 10.2903/j.efsa.2009.1224, lire en ligne, consulté le )
  • (en) EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), « Scientific Opinion on the substantiation of health claims related to vitamin A (including β-carotene) and maintenance of normal vision (ID 4239, 4701), maintenance of normal skin and mucous membranes (ID 4660, 4702), and maintenance of normal hair (ID 466: Vitamin A related health claims », EFSA Journal, vol. 8, no 10,‎ , p. 1754 (DOI 10.2903/j.efsa.2010.1754, lire en ligne, consulté le )
  • Emma P. Halmos, Victoria A. Power, Susan J. Shepherd et Peter R. Gibson, « A diet low in FODMAPs reduces symptoms of irritable bowel syndrome », Gastroenterology, vol. 146, no 1,‎ , p. 67–75.e5 (ISSN 1528-0012, PMID 24076059, DOI 10.1053/j.gastro.2013.09.046, lire en ligne, consulté le )
  • (en) Alon Friedman et Yonatan Serlin, « Breaching the Blood-Brain Barrier as a Gate to Psychiatric Disorder », sur Cardiovascular Psychiatry and Neurology, (PMID 19936105, PMCID PMC2775634, DOI 10.1155/2009/278531, consulté le )
  • Z Liu, N Li et J Neu, « Tight junctions, leaky intestines, and pediatric diseases », Acta Paediatrica, vol. 94, no 4,‎ , p. 386–393 (ISSN 0803-5253, DOI 10.1111/j.1651-2227.2005.tb01904.x, lire en ligne, consulté le )
  • (en) Dario Siniscalco, Anna Lisa Brigida et Nicola Antonucci, « Autism and neuro-immune-gut link », Molecular 2018, Vol. 5, Pages 166-172,‎ (DOI 10.3934/molsci.2018.2.166, lire en ligne, consulté le )
  • (en) Tevfik Noyan, Abdullah Daglı, Emine Yurdakul Ertürk et Abdullah Erdil, « Increased Serum Zonulin Levels as an Intestinal Permeability Marker in Autistic Subjects », The Journal of Pediatrics, vol. 188,‎ , p. 240–244 (ISSN 0022-3476 et 1090-123X, PMID 28502607, DOI 10.1016/j.jpeds.2017.04.004, lire en ligne, consulté le )
  • (en) Emmanuelle Waubant, « Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis », sur Disease Markers, (PMID 17124345, PMCID PMC3850823, DOI 10.1155/2006/709869, consulté le )
  • Akobeng, Elawad et Gordon, « Glutamine for induction of remission in Crohn's disease. », The Cochrane Database of Systematic Reviews, vol. 2,‎ , p. CD007348 (PMID 26853855, DOI 10.1002/14651858.CD007348.pub2, lire en ligne)
  • « Non-dietary therapeutic clinical trials in coeliac disease », Eur J Intern Med., vol. 23, no 1,‎ , p. 9–14 (PMID 22153524, DOI 10.1016/j.ejim.2011.08.030)

hindawi.com

issn.org

portal.issn.org

  • A. Goebel, S. Buhner, R. Schedel et H. Lochs, « Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome », Rheumatology, vol. 47, no 8,‎ , p. 1223–1227 (ISSN 1462-0324 et 1462-0332, DOI 10.1093/rheumatology/ken140, lire en ligne, consulté le )
  • (en) Laura de Magistris, Valeria Familiari, Antonio Pascotto et Anna Sapone, « Alterations of the Intestinal Barrier in Patients With Autism Spectrum Disorders and in Their First-degree Relatives », Journal of Pediatric Gastroenterology and Nutrition, vol. 51, no 4,‎ , p. 418–424 (ISSN 0277-2116, DOI 10.1097/MPG.0b013e3181dcc4a5, lire en ligne, consulté le )
  • Mariarosaria Di Pierro, Ruliang Lu, Sergio Uzzau et Wenle Wang, « Zonula Occludens Toxin Structure-Function Analysis », Journal of Biological Chemistry, vol. 276, no 22,‎ , p. 19160–19165 (ISSN 0021-9258 et 1083-351X, DOI 10.1074/jbc.m009674200, lire en ligne, consulté le )
  • (en) Mohan K. Raizada, Carl J. Pepine, Richard C. Holbert et Elaine M. Richards, « Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression », Gut, vol. 67, no 8,‎ , p. 1555–1557 (ISSN 0017-5749 et 1468-3288, PMID 28814485, PMCID PMC5851874, DOI 10.1136/gutjnl-2017-314759, lire en ligne, consulté le )
  • Khaleghi, Ju, Lamba et Murray, « The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate », Therapeutic Advances in Gastroenterology, vol. 9, no 1,‎ , p. 37–49 (ISSN 1756-283X, PMID 26770266, PMCID 4699279, DOI 10.1177/1756283X15616576)
  • Jose L Barboza, Michael S Okun et Baharak Moshiree, « The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease », Expert Opinion on Pharmacotherapy, vol. 16, no 16,‎ , p. 2449–2464 (ISSN 1465-6566 et 1744-7666, DOI 10.1517/14656566.2015.1086747, lire en ligne, consulté le )
  • Eveline Deloose et Jan Tack, « Redefining the functional roles of the gastrointestinal migrating motor complex and motilin in small bacterial overgrowth and hunger signaling », American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 310, no 4,‎ , G228–G233 (ISSN 0193-1857 et 1522-1547, DOI 10.1152/ajpgi.00212.2015, lire en ligne, consulté le )
  • Emma P. Halmos, Victoria A. Power, Susan J. Shepherd et Peter R. Gibson, « A diet low in FODMAPs reduces symptoms of irritable bowel syndrome », Gastroenterology, vol. 146, no 1,‎ , p. 67–75.e5 (ISSN 1528-0012, PMID 24076059, DOI 10.1053/j.gastro.2013.09.046, lire en ligne, consulté le )
  • Z Liu, N Li et J Neu, « Tight junctions, leaky intestines, and pediatric diseases », Acta Paediatrica, vol. 94, no 4,‎ , p. 386–393 (ISSN 0803-5253, DOI 10.1111/j.1651-2227.2005.tb01904.x, lire en ligne, consulté le )
  • (en) Tevfik Noyan, Abdullah Daglı, Emine Yurdakul Ertürk et Abdullah Erdil, « Increased Serum Zonulin Levels as an Intestinal Permeability Marker in Autistic Subjects », The Journal of Pediatrics, vol. 188,‎ , p. 240–244 (ISSN 0022-3476 et 1090-123X, PMID 28502607, DOI 10.1016/j.jpeds.2017.04.004, lire en ligne, consulté le )

jpeds.com

nhs.uk

nih.gov

ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

ovid.com

insights.ovid.com

  • (en) Laura de Magistris, Valeria Familiari, Antonio Pascotto et Anna Sapone, « Alterations of the Intestinal Barrier in Patients With Autism Spectrum Disorders and in Their First-degree Relatives », Journal of Pediatric Gastroenterology and Nutrition, vol. 51, no 4,‎ , p. 418–424 (ISSN 0277-2116, DOI 10.1097/MPG.0b013e3181dcc4a5, lire en ligne, consulté le )

uclan.ac.uk

clok.uclan.ac.uk

wiley.com

doi.wiley.com

  • (en) EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), « Scientific Opinion on the substantiation of health claims related to riboflavin (vitamin B2) and contribution to normal energy-yielding metabolism (ID 29, 35, 36, 42), contribution to normal metabolism of iron (ID 30, 37), maintenance of normal skin and m: Riboflavin related health claims », EFSA Journal, vol. 8, no 10,‎ , p. 1814 (DOI 10.2903/j.efsa.2010.1814, lire en ligne, consulté le )
  • (en) EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), « Scientific Opinion on the substantiation of health claims related to niacin and energy-yielding metabolism (ID 43, 49, 54), function of the nervous system (ID 44, 53), maintenance of the skin and mucous membranes (ID 45, 48, 50, 52), maintenance of normal: Niacin related health claims », EFSA Journal, vol. 7, no 10,‎ , p. 1224 (DOI 10.2903/j.efsa.2009.1224, lire en ligne, consulté le )
  • (en) EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), « Scientific Opinion on the substantiation of health claims related to vitamin A (including β-carotene) and maintenance of normal vision (ID 4239, 4701), maintenance of normal skin and mucous membranes (ID 4660, 4702), and maintenance of normal hair (ID 466: Vitamin A related health claims », EFSA Journal, vol. 8, no 10,‎ , p. 1754 (DOI 10.2903/j.efsa.2010.1754, lire en ligne, consulté le )